The Agency for Science, Technology and Research (A*STAR)

Singapore's lead public sector R&D agency. Through open innovation, A*STAR collaborates with partners in both the public and private sectors to benefit the economy and society in Singapore. SCG has a worldwide licence agreement with A*STAR to develop and commercialise iPSC-derived cell therapy products. In addition, together with the A*STAR's Bioprocessing Technology Institute (BTI) and Institute of Molecular and Cell Biology (IMCB), SCG collaborates to advance antibody product development and accelerate clinical translation of immune-cell based therapy.

Helmholtz Zentrum München

As part of the biggest research organization in Germany- Helmholtz Association, is a research center with the mission to discover personalized medical solutions for the prevention and treatment of diseases and promote a healthier society. SCG have an exclusive worldwide collaboration and license agreement with Helmholtz Zentrum München to develop and commercialize CAR T and TCR T cell therapy products targeting hepatocellular carcinoma and hepatitis B. In addition, together with the Technical University of Munich and German Cancer Research Center, SCG entered an exclusive worldwide license agreement to develop bi/multiple specific antibodies against HBV and associated conditions.

The Technical University of Munich (TUM)

Is one of Europe's top universities. It focuses on engineering sciences, natural sciences, life sciences and forges strong links with industry and scientific institutions across the world. Together with the Helmholtz Zentrum München and German Cancer Research Center, SCG entered an exclusive worldwide license agreement to develop bi/multiple specific antibodies against HBV and associated conditions.

German Cancer Research Center (DKFZ)

Is the largest biomedical research institute in Germany focusing on cancer research. Together with the Helmholtz Zentrum München and the Technical University of Munich, SCG entered an exclusive worldwide license agreement to develop bi/multiple specific antibodies against HBV and associated conditions.